Note: This story has been updated March 6, 2025, to correct a quote from Mindy Henderson, MDA vice president of…
Mary Chapman
Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Mary Chapman
The inaugural Lambert-Eaton myasthenic syndrome (LEMS) Awareness Day — which will be held each year on March 30 to…
The U.S. Patent and Trademark Office has sent a notice of allowance for two additional patents for Firdapse (amifampridine),…
When United Nations (UN) member states gathered recently to discuss advancing universal health coverage by 2030, a side event was…
The U.K.-based myasthenia patient organization Myaware will host an online support meeting on Aug. 9 for individuals living…
People with a rare disease who do not adhere to their therapeutic regimen primarily do so intentionally, rather than due…
Months after a Federal Court of Appeal of Canada decision restored the availability of the Lambert-Eaton myasthenic syndrome (LEMS) treatment…
Delaware’s lieutenant governor, Bethany Hall-Long, PhD, is applauding the passage in the state House of Representatives of a measure that…
Minnesota Twins outfielder Michael A. Taylor is stepping up to the plate on behalf of people with rare diseases like…
The National Organization for Rare Disorders (NORD) has selected four patient advocacy organizations to join its IAMRAREÂ platform and…